What is Bionexus Gene La's earnings per share (EPS)?

Bionexus Gene La (BGLC) reported diluted earnings per share of $-0.09 for fiscal year 2024. This represents a 45.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bionexus Gene La Financials

BGLC

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Bionexus Gene La (BGLC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 33/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Bionexus Gene La has an operating margin of -16.6%, meaning the company retains $-17 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -26.5% the prior year.

Growth

Bionexus Gene La's revenue declined 2.7% year-over-year, from $9.8M to $9.5M. This contraction results in a growth score of 29/100.

Leverage

Bionexus Gene La carries a low D/E ratio of 0.25, meaning only $0.25 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.81, Bionexus Gene La holds $3.81 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 75/100.

Cash Flow

While Bionexus Gene La generated -$2.2M in operating cash flow, capex of $227K consumed most of it, leaving -$2.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Bionexus Gene La generates a -19.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -27.2% the prior year.

Piotroski F-Score Weak

2/9

Bionexus Gene La passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

1.40x

For every $1 of reported earnings, Bionexus Gene La generates $1.40 in operating cash flow (-$2.2M OCF vs -$1.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$9.5M

YoY-2.7%

5Y CAGR+137.1%

Bionexus Gene La generated $9.5M in revenue in fiscal year 2024. This represents a decrease of 2.7% from the prior year.

EBITDA

-$1.5M

YoY+39.5%

Bionexus Gene La's EBITDA was -$1.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 39.5% from the prior year.

Net Income

-$1.6M

YoY+39.2%

Bionexus Gene La reported -$1.6M in net income in fiscal year 2024. This represents an increase of 39.2% from the prior year.

EPS (Diluted)

$-0.09

YoY+45.8%

Bionexus Gene La earned $-0.09 per diluted share (EPS) in fiscal year 2024. This represents an increase of 45.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$2.5M

YoY-24.8%

Bionexus Gene La generated -$2.5M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 24.8% from the prior year.

Cash & Debt

$1.6M

YoY-64.9%

5Y CAGR+13.0%

Bionexus Gene La held $1.6M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

18M

YoY+1.7%

Bionexus Gene La had 18M shares outstanding in fiscal year 2024. This represents an increase of 1.7% from the prior year.

Margins & Returns

Gross Margin

13.6%

YoY-0.1pp

5Y CAGR-30.5pp

Bionexus Gene La's gross margin was 13.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the prior year.

Operating Margin

-16.6%

YoY+10.0pp

5Y CAGR+200.6pp

Bionexus Gene La's operating margin was -16.6% in fiscal year 2024, reflecting core business profitability. This is up 10.0 percentage points from the prior year.

Net Margin

-16.8%

YoY+10.1pp

5Y CAGR+177.3pp

Bionexus Gene La's net profit margin was -16.8% in fiscal year 2024, showing the share of revenue converted to profit. This is up 10.1 percentage points from the prior year.

Return on Equity

-19.2%

YoY+8.0pp

5Y CAGR+2.8pp

Bionexus Gene La's ROE was -19.2% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 8.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$48K

YoY-13.6%

Bionexus Gene La invested $48K in research and development in fiscal year 2024. This represents a decrease of 13.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$227K

YoY+51.9%

5Y CAGR+77.7%

Bionexus Gene La invested $227K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 51.9% from the prior year.

BGLC Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$9.5M-2.7%	$9.8M-10.6%	$10.9M-18.2%	$13.4M+17.3%	$11.4M+8872.0%	$127K
Cost of Revenue	$8.2M-2.6%	$8.4M-12.7%	$9.7M-12.9%	$11.1M+14.7%	$9.7M+13507.7%	$71K
Gross Profit	$1.3M-3.0%	$1.3M+5.6%	$1.3M-44.5%	$2.3M+31.8%	$1.7M+2977.3%	$56K
R&D Expenses	$48K-13.6%	$55K	N/A	N/A	N/A	N/A
SG&A Expenses	$2.0M-19.2%	$2.4M+41.2%	$1.7M+35.4%	$1.3M-4.2%	$1.3M+273.7%	$357K
Operating Income	-$1.6M+39.3%	-$2.6M-790.7%	-$291K-127.6%	$1.1M-17.1%	$1.3M+562.0%	-$276K
Interest Expense	N/A	$14K+11.6%	$12K	N/A	N/A	N/A
Income Tax	-$3K+83.8%	-$22K+58.8%	-$52K+82.0%	-$291K	N/A	$25K
Net Income	-$1.6M+39.2%	-$2.6M-638.6%	-$356K-147.4%	$752K-31.3%	$1.1M+543.9%	-$246K
EPS (Diluted)	$-0.09+45.8%	$-0.17	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$2.5M+12.5%	$2.3M+5.8%	$2.1M-15.3%	$2.5M-4.0%	$2.6M+33.2%	$2.0M-17.1%	$2.4M+4.8%	$2.3M
Cost of Revenue	$2.2M+14.5%	$1.9M+5.5%	$1.8M-19.0%	$2.2M-3.9%	$2.3M+36.7%	$1.7M-16.4%	$2.0M+0.5%	$2.0M
Gross Profit	$378K+2.6%	$368K+7.1%	$343K+11.1%	$309K-5.3%	$327K+13.1%	$289K-20.9%	$365K+36.9%	$267K
R&D Expenses	$15K+18.5%	$13K+3.4%	$12K-30.2%	$17K+66.6%	$10K+27.4%	$8K-28.6%	$11K	N/A
SG&A Expenses	$446K-13.8%	$517K+31.9%	$392K+27.7%	$307K-61.3%	$792K+41.8%	$559K+77.0%	$316K+115.9%	-$2.0M
Operating Income	-$703K-14.9%	-$611K+1.2%	-$618K-48.6%	-$416K+68.9%	-$1.3M-616.1%	$259K+427.9%	-$79K-130.7%	$258K
Interest Expense	N/A	N/A	N/A	N/A	$6K	N/A	$5K	N/A
Income Tax	$0	$0	$0+100.0%	-$41K-2708.7%	$2K-97.2%	$56K+377.0%	-$20K+79.5%	-$98K
Net Income	-$709K-15.1%	-$616K+1.1%	-$623K-79.0%	-$348K+74.1%	-$1.3M-775.7%	$199K+291.9%	-$104K-133.6%	$308K
EPS (Diluted)	$-0.40-15.2%	$-0.34-880.0%	$-0.04	N/A	$-0.75-762.8%	$0.11+1983.3%	$-0.01	N/A

BGLC Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$10.4M-8.5%	$11.4M+30.4%	$8.7M-8.7%	$9.6M-5.3%	$10.1M+721.6%	$1.2M
Current Assets	$7.4M-7.7%	$8.0M+33.6%	$6.0M-15.8%	$7.1M-10.5%	$8.0M+804.8%	$883K
Cash & Equivalents	$1.6M-64.9%	$4.5M+113.2%	$2.1M-0.2%	$2.1M-23.8%	$2.8M+224.5%	$859K
Inventory	$1.4M+22.0%	$1.1M+16.4%	$978K-35.8%	$1.5M+29.4%	$1.2M+15416.8%	$8K
Accounts Receivable	$1.4M+72.1%	$800K-72.1%	$2.9M-14.6%	$3.4M	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.1M+21.2%	$1.7M-16.1%	$2.1M-13.3%	$2.4M-30.7%	$3.5M+3071.7%	$109K
Current Liabilities	$2.0M+19.6%	$1.6M-18.6%	$2.0M-13.9%	$2.3M-31.0%	$3.4M+6441.3%	$52K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.3M-13.8%	$9.7M+44.9%	$6.7M-7.2%	$7.2M+7.8%	$6.7M+493.6%	$1.1M
Retained Earnings	-$3.4M-86.7%	-$1.8M-259.5%	$1.2M-23.5%	$1.5M+98.8%	$761K+328.3%	-$333K

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$7.6M-19.1%	$9.4M-0.6%	$9.5M-9.1%	$10.4M-5.1%	$11.0M-1.3%	$11.1M-0.2%	$11.2M-2.1%	$11.4M
Current Assets	$5.6M-11.8%	$6.4M-2.5%	$6.5M-12.0%	$7.4M+5.6%	$7.0M-10.2%	$7.8M-0.8%	$7.9M-1.8%	$8.0M
Cash & Equivalents	$1.2M+41.6%	$814K-61.0%	$2.1M+32.0%	$1.6M-61.7%	$4.1M-23.6%	$5.4M+22.0%	$4.4M-1.7%	$4.5M
Inventory	$1.0M-17.1%	$1.2M+3.1%	$1.2M-15.1%	$1.4M0.0%	$1.4M+34.5%	$1.0M-4.1%	$1.1M-5.3%	$1.1M
Accounts Receivable	$1.5M-17.8%	$1.9M+28.4%	$1.4M+4.8%	$1.4M-3.4%	$1.4M+44.3%	$988K+17.7%	$840K+5.0%	$800K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$805K-57.6%	$1.9M+11.2%	$1.7M-19.1%	$2.1M+31.4%	$1.6M+0.8%	$1.6M-12.3%	$1.8M+4.3%	$1.7M
Current Liabilities	$678K-61.4%	$1.8M+12.7%	$1.6M-20.0%	$2.0M+37.9%	$1.4M+1.1%	$1.4M-18.5%	$1.7M+5.2%	$1.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.8M-9.4%	$7.5M-3.2%	$7.8M-6.6%	$8.3M-11.3%	$9.4M-1.7%	$9.5M+2.2%	$9.3M-3.2%	$9.7M
Retained Earnings	-$5.4M-15.1%	-$4.7M-15.2%	-$4.1M-18.1%	-$3.4M-11.3%	-$3.1M-76.9%	-$1.7M+10.2%	-$1.9M-5.6%	-$1.8M

BGLC Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$2.2M-22.6%	-$1.8M-430.2%	$552K+5923.6%	$9K-98.3%	$553K+354.4%	-$217K
Capital Expenditures	$227K+51.9%	$149K	$0-100.0%	$3K-99.3%	$422K+3189.5%	$13K
Free Cash Flow	-$2.5M-24.8%	-$2.0M-457.3%	$552K+9098.6%	$6K-95.4%	$131K+157.0%	-$230K
Investing Cash Flow	$418K+123.3%	-$1.8M-298.3%	-$450K+8.2%	-$491K-137.2%	$1.3M+10398.7%	-$13K
Financing Cash Flow	$145K-97.7%	$6.3M+5701.1%	$108K+483.3%	-$28K-470.5%	-$5K+97.3%	-$181K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$1.2M-67.7%	-$738K+10.5%	-$824K-1153.8%	$78K+104.9%	-$1.6M-138.4%	-$672K-1709.5%	-$37K+95.3%	-$783K
Capital Expenditures	$5K-74.4%	$21K+137.1%	$9K+125.1%	$4K-98.0%	$199K+10766.8%	$2K-91.6%	$22K+2242.0%	$937
Free Cash Flow	-$1.2M-63.7%	-$759K+8.9%	-$833K-1223.1%	$74K+104.1%	-$1.8M-167.3%	-$674K-1040.7%	-$59K+92.5%	-$783K
Investing Cash Flow	$995K+3586.1%	-$29K-82.4%	-$16K-102.8%	$554K+372.9%	-$203K-420.9%	$63K+1634.5%	$4K+100.3%	-$1.4M
Financing Cash Flow	$34K+3419.1%	-$1K-19.8%	-$860+38.0%	-$1K+97.5%	-$56K-131.9%	$175K+551.4%	$27K-94.9%	$532K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BGLC Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	13.6%-0.1pp	13.6%+2.1pp	11.5%-5.4pp	17.0%+1.9pp	15.1%-28.9pp	44.0%
Operating Margin	-16.6%+10.0pp	-26.5%-23.9pp	-2.7%-10.6pp	7.9%-3.3pp	11.2%+228.4pp	-217.2%
Net Margin	-16.8%+10.1pp	-26.9%-23.7pp	-3.3%-8.9pp	5.6%-4.0pp	9.6%+203.8pp	-194.1%
Return on Equity	-19.2%+8.0pp	-27.2%-21.9pp	-5.3%-15.8pp	10.5%-6.0pp	16.4%+38.4pp	-22.0%
Return on Assets	-15.3%+7.7pp	-23.1%-19.0pp	-4.1%-11.9pp	7.8%-3.0pp	10.8%+30.8pp	-20.0%
Current Ratio	3.81-1.1	4.93+1.9	3.00-0.1	3.07+0.7	2.37-14.7	17.11
Debt-to-Equity	0.25+0.1	0.18-0.1	0.31-0.0	0.33-0.2	0.52+0.4	0.10
FCF Margin	-25.9%-5.7pp	-20.2%-25.2pp	5.1%+5.0pp	0.0%-1.1pp	1.1%+182.4pp	-181.2%

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	14.8%-1.4pp	16.3%+0.2pp	16.1%+3.8pp	12.3%-0.2pp	12.4%-2.2pp	14.6%-0.7pp	15.3%+3.6pp	11.7%
Operating Margin	-27.6%-0.6pp	-27.1%+1.9pp	-28.9%-12.4pp	-16.5%+34.4pp	-50.8%-64.0pp	13.1%+16.4pp	-3.3%-14.7pp	11.3%
Net Margin	-27.9%-0.6pp	-27.3%+1.9pp	-29.2%-15.4pp	-13.8%+37.3pp	-51.1%-61.2pp	10.1%+14.4pp	-4.4%-17.9pp	13.6%
Return on Equity	-10.4%-2.2pp	-8.2%-0.2pp	-8.0%-3.8pp	-4.2%+10.1pp	-14.3%-16.4pp	2.1%+3.2pp	-1.1%-4.3pp	3.2%
Return on Assets	-9.3%-2.8pp	-6.5%+0.0pp	-6.6%-3.2pp	-3.3%+8.9pp	-12.2%-14.0pp	1.8%+2.7pp	-0.9%-3.6pp	2.7%
Current Ratio	8.30+4.7	3.63-0.6	4.19+0.4	3.81-1.2	4.98-0.6	5.60+1.0	4.61-0.3	4.93
Debt-to-Equity	0.12-0.1	0.25+0.0	0.22-0.0	0.25+0.1	0.170.0	0.17-0.0	0.19+0.0	0.18
FCF Margin	-48.9%-15.3pp	-33.6%+5.4pp	-39.0%-41.9pp	2.9%+71.5pp	-68.5%-34.4pp	-34.1%-31.7pp	-2.5%+32.0pp	-34.5%

Similar Companies

Cn Energy Group Inc CNEY

$3.3M

Bolt Projects Holdings Inc BSLK

$2.5M

Bon Natural Life Ltd BON

$10.4M

Senestech Inc SNES

$8.6M

Northern Techn NTIC

$75.2M

Frequently Asked Questions

What is Bionexus Gene La's annual revenue?

Bionexus Gene La (BGLC) reported $9.5M in total revenue for fiscal year 2024. This represents a -2.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bionexus Gene La's revenue growing?

Bionexus Gene La (BGLC) revenue declined by 2.7% year-over-year, from $9.8M to $9.5M in fiscal year 2024.

Is Bionexus Gene La profitable?

No, Bionexus Gene La (BGLC) reported a net income of -$1.6M in fiscal year 2024, with a net profit margin of -16.8%.

What is Bionexus Gene La's EBITDA?

Bionexus Gene La (BGLC) had EBITDA of -$1.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Bionexus Gene La's gross margin?

Bionexus Gene La (BGLC) had a gross margin of 13.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bionexus Gene La's operating margin?

Bionexus Gene La (BGLC) had an operating margin of -16.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Bionexus Gene La's net profit margin?

Bionexus Gene La (BGLC) had a net profit margin of -16.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Bionexus Gene La's return on equity (ROE)?

Bionexus Gene La (BGLC) has a return on equity of -19.2% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Bionexus Gene La's free cash flow?

Bionexus Gene La (BGLC) generated -$2.5M in free cash flow during fiscal year 2024. This represents a -24.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bionexus Gene La's operating cash flow?

Bionexus Gene La (BGLC) generated -$2.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Bionexus Gene La's total assets?

Bionexus Gene La (BGLC) had $10.4M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Bionexus Gene La's capital expenditures?

Bionexus Gene La (BGLC) invested $227K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Bionexus Gene La spend on research and development?

Bionexus Gene La (BGLC) invested $48K in research and development during fiscal year 2024.

How many shares does Bionexus Gene La have outstanding?

Bionexus Gene La (BGLC) had 18M shares outstanding as of fiscal year 2024.

What is Bionexus Gene La's current ratio?

Bionexus Gene La (BGLC) had a current ratio of 3.81 as of fiscal year 2024, which is generally considered healthy.

What is Bionexus Gene La's debt-to-equity ratio?

Bionexus Gene La (BGLC) had a debt-to-equity ratio of 0.25 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bionexus Gene La's return on assets (ROA)?

Bionexus Gene La (BGLC) had a return on assets of -15.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Bionexus Gene La's cash runway?

Based on fiscal year 2024 data, Bionexus Gene La (BGLC) had $1.6M in cash against an annual operating cash burn of $2.2M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Bionexus Gene La's Piotroski F-Score?

Bionexus Gene La (BGLC) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bionexus Gene La's earnings high quality?

Bionexus Gene La (BGLC) has an earnings quality ratio of 1.40x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Bionexus Gene La?

Bionexus Gene La (BGLC) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.